
    
      This First in- human study of AMG 172 will be conducted in two parts: Part 1 (dose
      exploration) and Part 2 (dose expansion). Part 1 of the study is aimed at evaluating the
      safety, tolerability and PK of AMG 172 given every two weeks and every three weeks in
      subjects with relapsed / refractory cc RCC, and Part 2 is aimed at evaluating safety,
      tolerability, PK and response rate in subjects treated at the MTD established in Part 1 for
      either every two week or every three week dosing. Up to 48 subjects may be enrolled in Part
      1, and up to 30 subjects may be enrolled in Part 2. The dose of AMG 172 utilized in Part 2
      will be dependent upon data obtained in Part 1 of the study.
    
  